Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 5 | 2017 | 420 | 0.650 |
Why?
|
| Hepatitis B Vaccines | 2 | 2010 | 42 | 0.570 |
Why?
|
| Genital Neoplasms, Female | 3 | 2015 | 46 | 0.550 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2017 | 52 | 0.430 |
Why?
|
| Hepatitis B Antibodies | 1 | 2010 | 24 | 0.340 |
Why?
|
| Needles | 1 | 2010 | 51 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 237 | 0.330 |
Why?
|
| PAX2 Transcription Factor | 1 | 2009 | 27 | 0.320 |
Why?
|
| Intestinal Perforation | 1 | 2009 | 56 | 0.310 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 2008 | 3 | 0.290 |
Why?
|
| Twins | 1 | 2008 | 69 | 0.280 |
Why?
|
| Thrombophlebitis | 1 | 2007 | 21 | 0.280 |
Why?
|
| Skin, Artificial | 1 | 2006 | 7 | 0.270 |
Why?
|
| Cesarean Section | 2 | 2017 | 390 | 0.250 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2006 | 60 | 0.250 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 198 | 0.250 |
Why?
|
| Immunization Programs | 1 | 2005 | 63 | 0.230 |
Why?
|
| School Health Services | 1 | 2005 | 99 | 0.230 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 256 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2005 | 161 | 0.220 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1534 | 0.200 |
Why?
|
| Health Promotion | 1 | 2005 | 386 | 0.190 |
Why?
|
| Obesity | 1 | 2010 | 2244 | 0.150 |
Why?
|
| Poverty | 2 | 2015 | 421 | 0.140 |
Why?
|
| Salpingo-oophorectomy | 1 | 2017 | 10 | 0.140 |
Why?
|
| Peritoneum | 1 | 2017 | 37 | 0.140 |
Why?
|
| Omentum | 1 | 2017 | 48 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 1245 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 129 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 206 | 0.120 |
Why?
|
| Female | 14 | 2018 | 66709 | 0.120 |
Why?
|
| Medically Underserved Area | 1 | 2015 | 89 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 80 | 0.120 |
Why?
|
| Placenta Accreta | 1 | 2017 | 158 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 439 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 669 | 0.100 |
Why?
|
| Survivors | 1 | 2015 | 339 | 0.100 |
Why?
|
| Neoplasms | 1 | 2007 | 2794 | 0.100 |
Why?
|
| Adult | 7 | 2017 | 29465 | 0.090 |
Why?
|
| Prognosis | 3 | 2011 | 4684 | 0.090 |
Why?
|
| Humans | 15 | 2018 | 125116 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 1023 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2011 | 1111 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 12273 | 0.080 |
Why?
|
| CA-125 Antigen | 1 | 2008 | 15 | 0.070 |
Why?
|
| Equipment Design | 1 | 2010 | 590 | 0.070 |
Why?
|
| Middle Aged | 6 | 2017 | 26682 | 0.070 |
Why?
|
| Pregnancy, Multiple | 1 | 2008 | 47 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 130 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 682 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1066 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1294 | 0.060 |
Why?
|
| Catheterization | 1 | 2007 | 226 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2011 | 1757 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2011 | 1035 | 0.060 |
Why?
|
| Texas | 3 | 2015 | 3571 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1704 | 0.060 |
Why?
|
| Fetofetal Transfusion | 1 | 2008 | 194 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1095 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 596 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1554 | 0.060 |
Why?
|
| Proteomics | 1 | 2008 | 506 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2018 | 16342 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1114 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 515 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2009 | 2814 | 0.050 |
Why?
|
| Pregnancy | 2 | 2017 | 7221 | 0.040 |
Why?
|
| Aged | 3 | 2017 | 19661 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6541 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.040 |
Why?
|
| Carboplatin | 1 | 2017 | 77 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2017 | 64 | 0.030 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2017 | 14 | 0.030 |
Why?
|
| Isotonic Solutions | 1 | 2017 | 35 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 45 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 41 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 50 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 71 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2017 | 130 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 73 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 116 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 153 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 9058 | 0.030 |
Why?
|
| Postpartum Hemorrhage | 1 | 2017 | 97 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 728 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 129 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2017 | 187 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 880 | 0.030 |
Why?
|
| Birth Weight | 1 | 2017 | 346 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 73 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 859 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3047 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 705 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 390 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1242 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 242 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1169 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 542 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2182 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 19419 | 0.020 |
Why?
|
| United States | 2 | 2018 | 10884 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 1292 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2011 | 21 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 252 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1155 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 605 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 820 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 874 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 1232 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3403 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1906 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 3675 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 2084 | 0.010 |
Why?
|
| Child | 1 | 2005 | 24614 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2518 | 0.010 |
Why?
|
| Male | 1 | 2010 | 61448 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8275 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 1985 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 5906 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10282 | 0.010 |
Why?
|